Alexander D. Guminski, MD, PhD, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Alexander D. Guminski, MD, PhD
Articles by Alexander D. Guminski, MD, PhD
Latest Updated Articles
Phase II Trial Shows Antitumor Activity With Cemiplimab in mCSCCPublished: July 11th 2019 | Updated: